drugset / Trial / NCT02323893

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

NCT02323893 ↗

Phase 1 Completed 6 enrolled CellSight Technologies, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG through time in healthy human volunteers.

Timeline

Start
2015-02
Primary completion
2017-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject F-ARAG Diagnostic / imaging agent — Intravenous

Indications